Biotech Values

[mcbio]

True; however, what’s even tougher these days is getting third-party payers to pay a high price for a branded drug that isn’t statsig superior to a drug that’s generic by the time the new branded drug hits the market.

Does the fact that the GSK/THRX drug is QD vs. a BID generic lessen these concerns to some degree, though? I've never followed THRX or this program closely so don't know if there may be safety advantages over Advair as well.